Clinical Trial

suPAR Michigan M2C2 Heterogeneity Validation Cohort Study

Completed
View on ClinicalTrials.gov →
Summary
This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19. Baseline suPAR measured using the suPARnostic TurbiLatex assay on the Roche cobas c501.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-03-09; most recent amendment 2026-03-19.
Trial Details
NCT Number NCT07466524
Lead Sponsor ViroGates A/S
Collaborators: University of Michigan, The University of Texas Medical Branch, Galveston
Conditions COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
Enrollment 367 participants
Start Date 2020-02-01
Primary Completion 2022-10-19 (estimated)
Study Completion 2022-10-19 (estimated)
Updated on ClinicalTrials.gov 2026-03-20